Cargando…
Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicity
Doxorubicin is an important anticancer drug in the clinic. Unfortunately, it causes cumulative and dose-dependent cardiotoxic side effects. As the population of cancer survivors who have been exposed to treatment continues to grow, there is increased interest in assessing the long-term cardiac effec...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561911/ https://www.ncbi.nlm.nih.gov/pubmed/31231550 http://dx.doi.org/10.1038/s41420-019-0182-6 |